RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mendus AB (publ) Stock

Mendus AB (publ) P/S 2024

Mendus AB (publ) P/S

93.74

Ticker

IMMU.ST

ISIN

SE0005003654

WKN

A1W59F

As of Sep 29, 2024, Mendus AB (publ)'s P/S ratio stood at 93.74, a 0% change from the 0 P/S ratio recorded in the previous year.

The Mendus AB (publ) P/S history

Mendus AB (publ) Aktienanalyse

What does Mendus AB (publ) do?

Immunicum AB is a biopharmaceutical company based in Stockholm, Sweden. It was founded in 2002 and has been working on developing innovative cancer therapies. The company aims to fight cancer cells in the body by targeting the activation of the body's immune system. Immunicum's business model is based on developing therapies that utilize allogeneic cell therapy. This involves using cells from donors to support specific processes in the body. Immunicum focuses on using dendritic cells as a model to specifically activate the body's immune system and fight cancer cells. The company has various divisions involved in the value chain of cancer therapy. One important area is the research and development of immunotherapies based on allogeneic cell therapy. Dendritic cells in particular are studied and further developed to enhance their effectiveness in fighting cancer. Another important division of Immunicum is clinical development, which involves conducting clinical trials to test and demonstrate the efficacy of the developed therapies in controlled studies. The results can then be used to seek approval for the therapies from regulatory authorities. Commercial development is another crucial area for Immunicum, involving the marketing and sale of the developed therapies. The company works closely with partners in the pharmaceutical industry to distribute the therapies worldwide and make them accessible to patients. Currently, the key product of Immunicum is the medication ilixadencel, which is a therapy based on allogeneic cell therapy that activates dendritic cells. Ilixadencel is being developed and tested as a treatment option for patients with renal cell carcinoma and glioblastoma. The medication is currently in clinical development and has already shown promising results in early studies. In addition to ilixadencel, Immunicum is also working on other products developed based on allogeneic cell therapy. This includes therapies for other types of cancer such as liver cancer and pancreatic cancer. The company has also achieved promising results in this area. Overall, Immunicum is an innovative biotech company aiming to develop new and effective cancer therapies. By specifically activating the body's immune system, their goal is to fight cancer cells and improve the quality of life for patients. The company has already made promising developments in this field and continues to work on improving the effectiveness of its therapies. Mendus AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Mendus AB (publ)'s P/S Ratio

Mendus AB (publ)'s Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Mendus AB (publ)'s P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Mendus AB (publ)'s stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Mendus AB (publ)’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Mendus AB (publ) stock

What is the price-to-earnings ratio of Mendus AB (publ)?

The price-earnings ratio of Mendus AB (publ) is currently 93.74.

How has the price-earnings ratio of Mendus AB (publ) changed compared to last year?

The price-to-earnings ratio of Mendus AB (publ) has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Mendus AB (publ) high compared to other companies?

Yes, the price-to-earnings ratio of Mendus AB (publ) is high compared to other companies.

How does an increase in the price-earnings ratio of Mendus AB (publ) affect the company?

An increase in the price-earnings ratio of Mendus AB (publ) would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Mendus AB (publ) affect the company?

A decrease in the price-earnings ratio of Mendus AB (publ) would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Mendus AB (publ)?

Some factors that influence the price-earnings ratio of Mendus AB (publ) are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Mendus AB (publ) pay?

Over the past 12 months, Mendus AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mendus AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Mendus AB (publ)?

The current dividend yield of Mendus AB (publ) is .

When does Mendus AB (publ) pay dividends?

Mendus AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mendus AB (publ)?

Mendus AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Mendus AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mendus AB (publ) located?

Mendus AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mendus AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mendus AB (publ) from 9/29/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Mendus AB (publ) pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Mendus AB (publ) in the year 2023?

In the year 2023, Mendus AB (publ) distributed 0 SEK as dividends.

In which currency does Mendus AB (publ) pay out the dividend?

The dividends of Mendus AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mendus AB (publ)

Our stock analysis for Mendus AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mendus AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.